Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harmane induces apoptosis through RRM2B and suppresses colorectal cancer progression.

mSystems·2026
Same author

Response to Letter regarding "Concerns regarding the applicability of ventilator-associated pneumonia prediction models".

American journal of infection control·2026
Same author

Hepatic SNHG9 links gut microbiota to liver protection in drug-induced liver injury.

Nature communications·2026
Same author

1-bit sampling acquisition method for coherent Doppler wind lidar.

Applied optics·2026
Same author

Gaussian-Fitting-Enabled High-Accuracy pH Detection for Light-Addressable Potentiometric Sensor.

Sensors (Basel, Switzerland)·2026
Same author

The relationship between social interaction patterns and cognitive trajectory in older adult: evidence from ELSA.

BMC public health·2026

Related Experiment Video

Updated: Jun 3, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Association between apolipoprotein E gene polymorphism and the dose for warfarin maintenance.

Shengwen Huang1, Baolin Chen, Daokang Xiang

  • 1Department of Laboratory Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China. hsw713@sina.com

Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|April 6, 2011
PubMed
Summary

Apolipoprotein E (apoE) gene polymorphism does not appear to be a major factor influencing individual warfarin maintenance doses. This study found no statistically significant differences in warfarin dosage requirements among different apoE genotypes.

Related Experiment Videos

Last Updated: Jun 3, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Area of Science:

  • Pharmacogenomics
  • Genetics
  • Clinical Pharmacology

Background:

  • Warfarin dosing requires careful individualization due to its narrow therapeutic index.
  • Genetic factors, such as apolipoprotein E (apoE) gene polymorphism, are investigated for their potential role in warfarin pharmacokinetics.
  • Understanding genetic influences can optimize warfarin therapy and reduce adverse events.

Purpose of the Study:

  • To examine the association between apolipoprotein E (apoE) gene polymorphism and the required maintenance dose of warfarin.
  • To determine if apoE genotypes correlate with variations in individual warfarin dosage needs.

Main Methods:

  • Genotyping of the apolipoprotein E (apoE) gene was performed using PCR/DHPLC assay in 249 patients on stable warfarin maintenance doses.
  • Warfarin maintenance doses were compared across different apoE genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4).

Main Results:

  • Allele frequencies for apoE were ε2 (9.44%), ε3 (84.74%), and ε4 (5.82%).
  • Patients with the ε2 genotype required slightly higher daily warfarin doses (3.24 ± 1.36 mg/d) compared to ε3 (2.91 ± 1.14 mg/d) or ε4 (2.98 ± 1.05 mg/d) groups.
  • These observed differences in warfarin doses among apoE genotype groups did not reach statistical significance (P > 0.05).

Conclusions:

  • Apolipoprotein E (apoE) gene polymorphism is unlikely to be a major determinant of individual warfarin maintenance doses.
  • Further research may be needed to identify other genetic or non-genetic factors influencing warfarin response.